Tags: Mild Cognitive Impairment

announcements

Ryan Institute for Neuroscience Receives Approval for Groundbreaking Clinical Trial

The ADDF-funded BEACON Study at the George & Anne Ryan Institute of Neuroscience received regulatory approval to conduct a clinical trial.

announcements

New Funding Focuses on Prevention

The Alzheimer's Drug Discovery Foundation awarded new funding to studies that focus on prevention.

blog

Top Five Highlights from AAIC 2018

The ADDF looks back at the 2018 Alzheimer's Association International Conference.

blog

Prevention: A Key to Conquering Alzheimer's

Dr. Howard Fillit explains the importance of prevention to the ADDF's mission and our current efforts, including clinical trials. 

blog

Closing in on a Cure: Dr. Michela Gallagher and AGB101

Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.

blog

Early-Stage Dementia Treatment Headed to Phase 3 Clinical Trial

ADDF-funded researchers are preparing for a phase 3 trial of what could become the first drug approved for mild cognitive impairment. 

announcements

New Approach to Delay Alzheimer’s Dementia Onset to Be Tested in Phase-3 Clinical Trial

The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.

blog

Alzheimer’s Versus Normal Cognitive Aging

The widespread misconception that Alzheimer's disease is a typical part of aging has serious ramifications for people's health and research into a cure.